| 1 |
Johnson PJ, Innes H, Hughes DM, Kalyuzhnyy A, Kumada T, Toyoda H. Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify. Br J Cancer 2022. [PMID: 35798825 DOI: 10.1038/s41416-022-01851-1] [Reference Citation Analysis]
|
| 2 |
Ahumada A, Rayón L, Usón C, Bañares R, Alonso Lopez S. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long? World J Gastroenterol 2021; 27(40): 6737-6749 [PMID: 34790004 DOI: 10.3748/wjg.v27.i40.6737] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 3 |
Costentin CE, Nahon P. HCC risk prediction using biomarkers in non-cirrhotic patients following HCV eradication: Reassuring the patient or the doctor? JHEP Rep 2021;3:100320. [PMID: 34308325 DOI: 10.1016/j.jhepr.2021.100320] [Reference Citation Analysis]
|
| 4 |
Melendez-Torres J, Singal AG. Early detection of hepatocellular carcinoma: roadmap for improvement. Expert Rev Anticancer Ther 2022. [PMID: 35514249 DOI: 10.1080/14737140.2022.2074404] [Reference Citation Analysis]
|
| 5 |
Lockart I, Yeo MGH, Hajarizadeh B, Dore GJ, Danta M. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. Hepatology 2022. [PMID: 35030279 DOI: 10.1002/hep.32341] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Lee K, Choi GH, Jang ES, Jeong SH, Kim JW. A scoring system for predicting hepatocellular carcinoma risk in alcoholic cirrhosis. Sci Rep 2022;12:1717. [PMID: 35110551 DOI: 10.1038/s41598-022-05196-w] [Reference Citation Analysis]
|
| 7 |
Johnson PJ. In search of an evidence base for HCC surveillance: Purity or pragmatism? J Hepatol 2021;74:1025-7. [PMID: 33766443 DOI: 10.1016/j.jhep.2021.02.018] [Reference Citation Analysis]
|
| 8 |
Stefanini B, Tonnini M, Serio I, Renzulli M, Tovoli F. Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement. Expert Rev Anticancer Ther 2022;:1-11. [PMID: 35263211 DOI: 10.1080/14737140.2022.2052276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Matthews C, Cross TJS. Before we can find an evidence base for HCC surveillance, we need to define our target demographic. J Hepatol 2021;75:1494-5. [PMID: 34242695 DOI: 10.1016/j.jhep.2021.06.042] [Reference Citation Analysis]
|
| 10 |
Johnson P, Zhou Q, Dao DY, Lo YMD. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35676420 DOI: 10.1038/s41575-022-00620-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Maan R, van der Meer AJ. Hepatocellular carcinoma (HCC) risk stratification after virological cure for hepatitis C virus (HCV)-induced cirrhosis: time to refine predictive models. Hepatobiliary Surg Nutr 2021;10:385-7. [PMID: 34159170 DOI: 10.21037/hbsn-21-95] [Reference Citation Analysis]
|
